Scarica l'app Stockscreener
1.41
6.62%
-0.10
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan
Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World
Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks
Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan
Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks
Immuneering Corp SEC 10-K Report - TradingView
Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com
Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan
Immuneering appoints Igor Matushansky as CMO - The Pharma Letter
Immuneering appoints new Chief Medical Officer - Investing.com
Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan
Immuneering Slides As Insider Purchases Lose Another US$186k - Yahoo Finance
Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20 - Armenian Reporter
Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Consensus PT from Analysts - Defense World
Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday - Defense World
Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter
Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - MSN
Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World
Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Immuneering's Cancer Drug Shows 50% Response Rate in Phase 2a Pancreatic Cancer Trial, Beating Benchmark - Stock Titan
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World
Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat
Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma
Wall Street-Heavily Traded - WDRB
Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks
Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Why Is Immuneering Stock Trading Higher On Tuesday? - AOL
Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News
Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):